Biotechnology company Partner Therapeutics Inc (PTx) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zenocutuzumab-zbco for the treatment of adults with advanced unresectable or metastatic cholangiocarcinoma.
Cholangiocarcinoma (CCA) is a rare, aggressive malignancy of the bile ducts, typically diagnosed at an advanced stage when curative options are limited.
Zenocutuzumab-zbco is being developed in a subset of patients with CCA harboring a neuregulin 1 (NRG1) gene fusion. It has shown activity in patients with cholangiocarcinoma harbouring NRG1 gene fusion.
Zenocutuzumab-zbco, marketed as BIZENGRI, received Breakthrough Therapy Designation from the FDA in October 2025 and was granted accelerated approval in December 2024 for adults with advanced unresectable or metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma harbouring NRG1 gene fusions following prior therapy.
UAE approves PYRUKYND for treatment of thalassaemia
Innovent Biologics' Jaypirca approved in China for new indication
Johnson & Johnson submits sBLA to FDA for first-ever treatment for wAIHA
AlzeCure's ACD440 granted EU orphan drug status for erythromelalgia
Armata Pharmaceuticals' AP-SA02 receives QIDP designation from US FDA
Immedica Pharma's Loargys (pegzilarginase-nbln) receives accelerated US FDA approval
Gossamer Bio reports topline Phase 3 PROSERA results for seralutinib in PAH
Organon licenses MIUDELLA IUD from Sebela Pharmaceuticals
Gilead to acquire Arcellx to gain full control of anito-cel
Novo Nordisk's CagriSema achieves 23% weight loss but misses primary endpoint in REDEFINE 4 trial
AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL
Vanda Pharmaceuticals' BYSANTI (milsaperidone) tablets receive US FDA approval